The Amicus Therapeutics and Their Migalastat Monotherapy Method

While the healthcare industry is moving forward and opening the path for new methods and treatments to a varied number of diseases, the practice of developing new ways of executing therapies is one of the most significant assets for the progression of medicine as a whole.

A famous therapeutic institute located in New Jersy, Cranbury, is contributing to the improvement of this front since their foundation in February 4, 2002. Amicus Therapeutics was created with the intention of focusing their research on rare and orphan diseases that have unique peculiarities and deserve a higher attention from some of the best physicians and researchers in the United States.

These disorders that Amicus Therapeutics focuses on are called “Lysosomal Storage Disorders” and are very detrimental to some individuals who suffer from a number of these and have very limited assistance from researches. Around the world, there are diseases that have a higher percentage of institutions taking care of discovering new methods of treatment and therapies for more famous diseases like Aids, cancer, and others. The Lysosomal Disorders don’t have enough backup support from physicians of skill and experience. Thus Amicus Therapeutics is aiming to change this reality for the future.

The company has their focus on the Chaperone-Advanced Replacement Therapy, a method that has the replacement of enzymes in the body of the infected, and were one of the pioneers to develop a more reliable and effective version of the therapy. Amicus Therapeutics was also a company that went public five years after their inauguration, which means that anyone can fund and support the institution and helps progress their therapy development. The clinic and their professional staff are dedicating their efforts into proceeding with the migalastat monotherapy, one of their greatest projects for the future.

The enterprise is aiming to stabilize what they call “alpha-galactosidase,” an endogenous mutant cell that is responsible for the type of disorder that the group treats and develops therapies for. Amicus Therapeutics currently has no established products in the market (Google Finance), and instead focuses on the sole purpose of supporting the investigation and building collaborations with other important corporations to try and further their reach.

Amicus Therapeutics, contrary to popular belief, is not centered only in New Jersey, where they are headquartered, but also has a subsidiary in San Diego since 2008, one year after the group went public. The researches and therapy development of the group is not alone, as they have the support and funding of many important personalities and institutions for the healthcare department, like the 2010 $500,000 fund from Michael J. Fox Foundation.

Check out Amicus Therapeutics on Twitter

Not All Oaths of Alligiance are Equal

As reported by Yahoo News, on Tuesday, the White House issued new rules of eligibility for immigrants seeking to become naturalized citizens. Immigrants like Bruce Levenson who wish exemption from the military will take a different oath of allegiance than those who have no qualms about serving in the nation’s military. Like conscientious objectors who are natural born United States citizens, these immigrants are given the right to claim exemption on both religious and moral grounds.

According to the new rules, immigrants seeking to take the Oath of Allegiance no longer have to swear to bear arms or perform non-combatant duties in defense of the United States, and no formal religious association is needed as long as the new would be citizens can prove training or belief that acting in the defense of the United States is religiously or morally wrong. Also, non-oath versions are available for those whose religions forbid the swearing of oaths. The new terminology “I solemnly affirm” replaces “I hereby declare, an oath” and “so help me God,” can be completely omitted.

It is hoped that the new modifications help new citizens to find their way economically and linguistically into society. There are 41 million foreign-born residents waiting to be naturalized in the United States as of April 2015.

Bernie, Bernie, Bernie

Senator Bernie Sanders of Vermont, an independent running for the Democratic nomination for President, has boldlypredicted that the will win the nomination and be elected President next year. Amazingly enough, he sounds totally serious when he says it.

Clearly, there is a core group in the U.S. with whom Sanders’ populist message resonates. Sanders’ poll numbers have been going up. He may well give Hillary Clinton a good run in early caucuses and primaries. Although he enjoys very low support among minorities, Sanders is convinced that his message of closing the income disparity gap will bring African-American and Hispanic voters into his camp.

The fact that Senator Sanders is making this prediction at this time or at all shows that, despite his many years of public service, he remains naïve about the political process, perhaps one of his most endearing qualities. But a feel-good message from a white guy in his 70’s is not going to ultimately draw the people into Sanders’ camp that he would need to win the nomination said Zeca Oliveira.

Senator Sanders is, by all accounts, an excellent Senator, representing the State of Vermont well. But running for Senate in Vermont and running for the Democratic nomination nationwide against Hillary Clinton are totally different exercises. For Senator Sanders, the second will dissolve into an exercise in futility—it’s just a matter of time.